These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6328985)

  • 1. Immediate regional blood flow distribution following angiotensin converting enzyme inhibition in patients with essential hypertension.
    Ventura HO; Frohlich ED; Messerli FH; Kobrin I; Kardon MB
    Am J Med; 1984 May; 76(5B):58-61. PubMed ID: 6328985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension.
    Ventura HO; Frohlich ED; Messerli FH; Kobrin I; Kardon MB
    Am J Cardiol; 1985 Apr; 55(8):1023-6. PubMed ID: 2984914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redistribution of regional blood flow following angiotensin-converting enzyme inhibition. Comparison of normal subjects and patients with heart failure.
    Faxon DP; Creager MA; Halperin JL; Bernard DB; Ryan TJ
    Am J Med; 1984 May; 76(5B):104-10. PubMed ID: 6203405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of converting enzyme inhibitor on hepatic blood flow in man.
    Crossley IR; Bihari D; Gimson AE; Westaby D; Richardson PJ; Williams R
    Am J Med; 1984 May; 76(5B):62-5. PubMed ID: 6328986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dilation of forearm blood vessels after angiotensin-converting-enzyme inhibition by captopril in hypertensive patients.
    Johns DW; Ayers CR; Williams SC
    Hypertension; 1984; 6(4):545-50. PubMed ID: 6086518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.
    Roberts DH; Tsao Y; Grimmer SF; Winstanley PA; Orme ML; Breckenridge AM
    Br J Clin Pharmacol; 1987 Aug; 24(2):163-72. PubMed ID: 2887190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats.
    Richer C; Doussau MP; Giudicelli JF
    Hypertension; 1983; 5(3):312-20. PubMed ID: 6188693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graded regional vasodilation with converting enzyme inhibitors in conscious spontaneously hypertensive rats.
    Lappe RW; Todt JA; Wendt RL
    J Pharmacol Exp Ther; 1985 Dec; 235(3):651-6. PubMed ID: 3001271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of renal hemodynamics in the antihypertensive effect of captopril.
    Ando K; Fujita T; Ito Y; Noda H; Yamashita K
    Am Heart J; 1986 Feb; 111(2):347-52. PubMed ID: 3511649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal hemodynamics in essential and renovascular hypertension. Influence of captopril.
    Hollenberg NK
    Am J Med; 1984 May; 76(5B):22-8. PubMed ID: 6328983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Captopril-induced changes in large arteries in essential hypertension.
    Simon AC; Levenson JA; Bouthier JL; Safar ME
    Am J Med; 1984 May; 76(5B):71-5. PubMed ID: 6328988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic and regional blood flow response to captopril in congestive heart failure.
    Levine TB; Olivari MT; Cohn JN
    Am J Med; 1984 May; 76(5B):38-42. PubMed ID: 6375361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.
    Campbell BC; Shepherd AN; Reid JL
    Br J Clin Pharmacol; 1982 Feb; 13(2):213-7. PubMed ID: 6277356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.
    MacGregor GA; Markandu ND; Roulston JE; Jones JC
    Br Med J; 1979 Nov; 2(6198):1106-9. PubMed ID: 229941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibitors. Disparities in the mechanism of their antihypertensive effect.
    Garavaglia GE; Messerli FH; Nunez BD; Schmieder RE; Frohlich ED
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):214S-216S. PubMed ID: 2843195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of blood pressure responses to captopril, an orally active converting enzyme inhibitor, in rats with various forms of experimental hypertension (author's transl)].
    Mikami H; Ogihara T; Kanda T; Higaki J; Naka T; Maruyama A; Hata T; Iwanaga K; Kumahara Y
    Nihon Naibunpi Gakkai Zasshi; 1980 Feb; 56(2):180-96. PubMed ID: 6245943
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and pharmacology of angiotensin converting enzyme inhibitors.
    Antonaccio MJ
    J Pharmacol; 1983; 14 Suppl 3():29-45. PubMed ID: 6323887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of inhibitors of angiotensin-converting enzyme on regional hemodynamics.
    Banas JS
    Am J Cardiol; 1992 Apr; 69(10):40C-45C. PubMed ID: 1546638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy of hypertension with angiotensin-converting enzyme inhibitors.
    Materson BJ
    Am J Med; 1984 Oct; 77(4A):128-34. PubMed ID: 6207725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure.
    Creager MA; Halperin JL; Bernard DB; Faxon DP; Melidossian CD; Gavras H; Ryan TJ
    Circulation; 1981 Sep; 64(3):483-9. PubMed ID: 6266691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.